P/E ratio for Akebia Therapeutics (AKBA)
P/E ratio as of April 2024 (TTM): -2.09
According to Akebia Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.09375. At the end of 2022 the company had a P/E ratio of -1.13.
P/E ratio history for Akebia Therapeutics from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.13 | -14.9% |
| 2021 | -1.33 | 31.52% |
| 2020 | -1.01 | -62.25% |
| 2019 | -2.68 | 11.19% |
| 2018 | -2.41 | -71.66% |
| 2017 | -8.50 | 193.85% |
| 2016 | -2.89 | -48.97% |
| 2015 | -5.67 | 2047.39% |
| 2014 | -0.2639 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -595.54% | 🇺🇸 USA |
 Novartis NVS | 26.1 | -1,344.35% | 🇨🇭 Switzerland |
 Amgen AMGN | 19.1 | -1,011.28% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | -0.8098 | -61.32% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.